Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Patent ExpiryapprovedNeedle-Free Insulin DeliveryNeedle-Free GLP-1 DeliveryPositive

AI Analysis

Summary

Hydreight Technologies announced a U.S. patent allowance for Insu Therapeutics' needle-free insulin and GLP-1 delivery technology, advancing the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights.

Outcome Details

U.S. patent allowance for needle-free insulin and GLP-1 delivery technology

Importance:5/10

Sentiment:

0.70

patentdelivery technologyinsulinGLP-1needle-freestrategic investment

Related Companies

$HYDTF

Read the original article

Published by PR Newswire Biotech on October 8, 2026 11:30 AM

Read Original